US drugmaker AbbVie has signed an agreement to acquire biotechnology company Aliada Therapeutics, which develops therapies for central nervous system (CNS) diseases using...
AbbVie has completed its acquisition of Cerevel Therapeutics. According to AbbVie, Cerevel's pipeline is highly complementary to its own existing neuroscience portfolio...
AbbVie has acquired Celsius Therapeutics, a privately held biotechnology company developing new therapies inflammatory diseases, for $250 million in cash. The transaction...
US drugmaker AbbVie and Chinese biopharmaceutical company FutureGen have entered into a license agreement to develop FG-M701, a next generation TL1A antibody for the...
Last week, AbbVie broke ground on a new Singapore manufacturing facility located in Singapore's Tuas Biomedical Park. The company will invest $223 million in the site...
In a move to complement its neuroscience portfolio, US drugmaker AbbVie has agreed to acquire Cerevel Therapeutics, which has a pipeline of multiple clinical-stage and...
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere...
With their triumphant advance, biosimilars are also setting in motion the usual market mechanisms. Biopharma interest groups warn against the automatic substitution of...
